Szwiec Marek, Marciniak Wojciech, Derkacz Róża, Huzarski Tomasz, Gronwald Jacek, Cybulski Cezary, Dębniak Tadeusz, Jakubowska Anna, Lener Marcin, Falco Michał, Kładny Józef, Baszuk Piotr, Duszyński Jerzy, Kotsopoulos Joanne, Narod Steven A, Lubiński Jan
Department of Surgery and Oncology, University of Zielona Góra, Zyty 28, 65-046 Zielona Góra, Poland.
Read-Gene S.A., 72-003 Grzepnica, Poland.
Nutrients. 2021 Mar 16;13(3):953. doi: 10.3390/nu13030953.
In a recent prospective study, we reported an association between a low serum selenium level and five-year survival among breast cancer patients. We now have updated the cohort to include 10-year survival rates. A blood sample was obtained from 538 women diagnosed with first primary invasive breast cancer between 2008 and 2015 in the region of Szczecin, Poland. Blood was collected before initiation of treatment. Serum selenium levels were quantified by mass spectroscopy. Each patient was assigned to one of four quartiles based on the distribution of serum selenium levels in the whole cohort. Patients were followed from diagnosis until death or last known alive (mean follow-up 7.9 years). The 10-year actuarial cumulative survival was 65.1% for women in the lowest quartile of serum selenium, compared to 86.7% for women in the highest quartile ( < 0.001 for difference). Further studies are needed to confirm the protective effect of selenium on breast cancer survival. If confirmed this may lead to an investigation of selenium supplementation on survival of breast cancer patients.
在最近一项前瞻性研究中，我们报告了血清硒水平低与乳腺癌患者五年生存率之间的关联。我们现在更新了队列，纳入了十年生存率。从2008年至2015年在波兰什切青地区被诊断为原发性浸润性乳腺癌的538名女性中采集了血样。在开始治疗前采集血液。通过质谱法定量血清硒水平。根据整个队列中血清硒水平的分布，将每位患者分配到四个四分位数之一。从诊断开始对患者进行随访，直至死亡或最后一次已知存活（平均随访7.9年）。血清硒处于最低四分位数的女性，其10年精算累积生存率为65.1%，而最高四分位数的女性为86.7%（差异<0.001）。需要进一步研究来证实硒对乳腺癌生存的保护作用。如果得到证实，这可能会促使对补充硒对乳腺癌患者生存的影响进行调查。
